Beijing Tong Ren Tang reports revenue and profit growth in first half

For the six months ended 30 June 2025, Beijing Tong Ren Tang Chinese Medicine Company Limited reported revenue of HK$761.7m, a 14.6% increase from HK$664.5m in the same period last year. Profit attributable to owners rose by 6.9% to HK$234.9m, up from HK$219.8m in 2024. Basic and diluted earnings per share also increased, reaching HK$0.28 compared to HK$0.26 in the prior year.

The company maintained a strong financial position with cash and bank balances of HK$2,005.5m as of 30 June 2025, a 10.2% increase from HK$1,819.8m at the end of 2024. Total assets amounted to HK$4,534.467m, with total equity at HK$4,222.210m. The current ratio stood at 18.2, reflecting ample financial resources. Capital expenditure for the period was HK$16.4m, primarily allocated to retail outlet renovations and machinery purchases.

Market expansion efforts included a new retail outlet in Yuen Long, Hong Kong, and product packaging redesigns to enhance appeal. The Group also actively participated in exhibitions and cultural events, promoting traditional Chinese medicine. In the first half of 2025, the company engaged in anti-counterfeiting efforts across approximately 140 e-commerce platforms and pharmacies in Hong Kong.